A study presented at the SGO Annual Meeting found that elderly women have higher rates of cervical cancer than previously thought, suggesting screening guidelines should be reconsidered.
The immune checkpoint inhibitor pembrolizumab demonstrated antitumor activity in a small trial of patients with advanced cervical cancer. The agent had a similar toxicity profile to that seen in other malignancies.
A large cohort study found no concerning safety issues associated with the use of human papillomavirus (HPV) vaccine in adult women. There was an increased rate of celiac disease, but this may be related to general underdiagnosis of the condition and its unmasking at vaccination visits.
The USPSTF issued a new draft recommendation for cervical cancer screening, recommending screening with cervical cytology every 3 years for women aged 21 to 29, and offering a choice between cytology every 3 years and high-risk human papillomavirus testing every 5 years for those aged 30 to 65 years.
The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.
Women who undergo HPV testing following a test showing abnormal cytology have earlier detection of high-grade cervical intraepithelial neoplasia, compared to those who do not undergo HPV testing.
Almost one quarter of long-term cervical cancer survivors reported experiencing chronic fatigue, according to a study conducted in Norway.
Women infected with the human immunodeficiency virus (HIV) are more likely to have human papillomavirus (HPV) infection that progresses to pre-cancerous cervical lesions.
The number of women who undergo regular screening for cervical cancer drops as they get older, and while this is acceptable if women have been followed regularly until the age of 65 years, women who are not up to date with screening should be screened when they are older.
Researchers evaluated cervical cancer screening rates in the severely mentally ill enrolled in California’s Medicaid program and noted lower than average rates in this population.